Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 4 1Phase 3 1Phase 2 1

Status

Recruiting 3Enrolling by invitation 1Active not recruiting 1

Sponsor Class

NIH 2INDUSTRY 2OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Thoracic 76Gastrointestinal 60Genitourinary 24Breast 12Gynecologic 7Sarcoma 6Tumor-Agnostic 5Head & Neck 5Other solid neoplasm 3Other hematologic neoplasm 2Dermatologic 2CNS 2Lymphoid 1Endocrine 1

Conditions

Neoplasms 3Neoplasm Metastasis 2

Interventions

pembrolizumab 24Specimen Handling 22Biopsy 22Magnetic Resonance Spectroscopy 19Paclitaxel 11Standard of Care 10Bevacizumab 10atezolizumab 9Carboplatin 9Nivolumab 8Cisplatin 8Blood Specimen Collection 8Surveys and Questionnaires 7Capecitabine 7Radiosurgery 6Pemetrexed 6Gemcitabine 6Cyclophosphamide 6durvalumab 5Taxes 5Irinotecan 5trastuzumab deruxtecan 4olaparib 4niraparib 4cabozantinib 4X-Rays 4Radiotherapy 4Oxaliplatin 4Leucovorin 4Ipilimumab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
durvalumab × Tumor-Agnostic × 90 days × Clear all
NCT06551142 2026-05-22

PanTumor-101

GlaxoSmithKline

Phase 1 Recruiting
845 enrolled
Tumor-Agnostic

Neoplasms

NCT05303532 2026-05-19

ROSY-D

AstraZeneca

Phase 3 Enrolling by invitation
214 enrolled
Tumor-Agnostic

Neoplasms

NCT03907475 2026-05-13

Durvalumab in Combination With Chemotherapy in Treating Patients With Advanced Solid Tumors, DURVA+ Trial

National Cancer Institute (NCI)

Phase 2 Recruiting
115 enrolled
Tumor-Agnostic

Neoplasm Metastasis

NCT03842228 2026-04-29

COD

National Cancer Institute (NCI)

Phase 1 Active not recruiting
39 enrolled 15 charts
Tumor-Agnostic

Neoplasm Metastasis

NCT06031233 2026-03-30

MINUTE

Isala

Phase 4 Recruiting
776 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡